AngioDynamics announced that its Relief feasibility study, which aims to evaluate the Nanoknife irreversible electroporation (IRE) platform as a minimally invasive treatment option for benign prostatic hyperplasia (BPH), has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA).

This approval marks a critical step for the company in expanding the application of its innovative technology. The Nanoknife IRE platform is designed to ablate targeted tissue with precision electric field energy while maximizing the protection of surrounding healthy structures. The Relief study for BPH will evaluate the safety and preliminary efficacy of this platform as a potential minimally invasive treatment option.Benign prostatic hyperplasia is a common, age-related male urinary system condition that can result in lower urinary tract symptoms, significantly affecting patients’ quality of life. Current standard treatments include medication and more invasive surgical procedures. If the study results are positive, Nanoknife IRE technology may offer patients a new treatment option that could be less traumatic.Obtaining IDE approval enables AngioDynamics to initiate patient recruitment for this clinical study in the United States. The study’s progress will be closely watched by the medical community and investors, as it may open new market opportunities for the company and validate the potential application of its technology platform in the urology field.